Want to see HK:0656 full AI Analyst Report?
Top Page
Fosun International
(0656)
Select Model
Select Model
Rating:51Neutral
Price Target:
HK$5.50
â–˛(1.48% Upside)
Action:Reiterated
Date:07/31/26
The score is held down primarily by weak financial performance: declining revenue, a widened net loss, and high leverage that reduces financial flexibility. Technicals provide moderate support as the stock is above major moving averages, and valuation is mixed—high yield is supportive but negative earnings (negative P/E) and balance sheet risk limit attractiveness.
Positive Factors
Diversified health, consumer and wealth platform
Fosun’s presence across health, consumer and wealth activities provides multiple operating engines and geographic exposure rather than reliance on one product line. This breadth can support resilience through differing economic cycles, while the portfolio structure offers opportunities to redeploy capital toward stronger businesses.
Negative Factors
Falling revenue and widening net losses
A declining top line combined with a materially wider net loss signals weakening earnings quality and limited current operating momentum. Continued contraction would reduce the resources available for reinvestment, make fixed financial costs harder to absorb, and challenge the sustainability of the group’s broad portfolio.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified health, consumer and wealth platform
Fosun’s presence across health, consumer and wealth activities provides multiple operating engines and geographic exposure rather than reliance on one product line. This breadth can support resilience through differing economic cycles, while the portfolio structure offers opportunities to redeploy capital toward stronger businesses.
Read all positive factors
Fosun International (0656) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$42.76B
Dividend Yield0.38%
Average Volume (3M)11.90M
Price to Earnings (P/E)―
Beta (1Y)0.97
Revenue Growth-1.33%
EPS Growth-409.12%
CountryHK
Employees103,900
SectorIndustrials
Sector Strength72
IndustryConglomerates
Share Statistics
EPS (TTM)-2.75
Shares Outstanding8,126,959,500
10 Day Avg. Volume10,681,928
30 Day Avg. Volume11,896,281
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.34
Price to Sales (P/S)0.18
P/FCF Ratio2.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$6.18Price Target Upside13.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.31
Revenue Forecast (FY)HK$185.21B
Fosun International Business Overview & Revenue Model
Company Description
Fosun International Limited operates as a global conglomerate, concentrating its diverse activities within the health, lifestyle, wealth management, and advanced manufacturing sectors. Its reach extends across Mainland China, Portugal, and various...
How the Company Makes Money
Fosun International makes money primarily through (1) operating revenue generated by its consolidated businesses and (2) investment-related income from its portfolio. Operating revenue is earned when its subsidiaries sell products and services acr...
Fosun International Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
34
Negative
Cash Flow
62
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 173.11B | 173.43B | 192.14B | 198.20B | 182.43B | 161.29B |
| Gross Profit | 48.72B | 47.84B | 51.60B | 50.80B | 47.31B | 55.65B |
| EBITDA | -12.93B | 14.64B | 329.02M | 30.50B | 1.02B | 4.05B |
| Net Income | -22.34B | -23.40B | -4.35B | 1.38B | -831.80M | 10.08B |
Balance Sheet | ||||||
| Total Assets | 712.16B | 716.54B | 796.53B | 808.39B | 806.38B | 806.28B |
| Cash, Cash Equivalents and Short-Term Investments | 214.03B | 97.43B | 133.09B | 133.27B | 150.38B | 166.93B |
| Total Debt | 218.31B | 250.68B | 241.86B | 233.57B | 245.92B | 257.87B |
| Total Liabilities | 538.83B | 548.17B | 598.99B | 599.81B | 607.30B | 603.16B |
| Stockholders Equity | 95.17B | 93.87B | 118.10B | 124.94B | 120.73B | 131.00B |
Cash Flow | ||||||
| Free Cash Flow | 7.04B | 15.42B | 15.61B | -3.35B | -5.45B | -9.64B |
| Operating Cash Flow | 10.60B | 26.59B | 26.88B | 9.82B | 1.76B | -3.32B |
| Investing Cash Flow | -12.62B | -61.13B | -126.97M | 17.59B | 35.58B | -536.96M |
| Financing Cash Flow | -3.10B | -15.25B | -14.27B | -39.67B | -38.12B | -3.66B |
Fosun International Technical Analysis
Positive
5.42
Price Trends
4.64
Positive
4.33
Positive
4.31
Positive
Market Momentum
0.18
Positive
58.84
Neutral
24.61
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0656, the sentiment is Positive. The current price of 5.42 is above the 20-day moving average (MA) of 5.21, above the 50-day MA of 4.64, and above the 200-day MA of 4.31, indicating a bullish trend. The MACD of 0.18 indicates Positive momentum. The RSI at 58.84 is Neutral, neither overbought nor oversold. The STOCH value of 24.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0656.
Fosun International Peers Comparison
UnderperformOutperform
Sector (63)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | HK$23.42B | 5.50 | 6.12% | 5.00% | 2.39% | 7.81% | |
75 Outperform | HK$126.48B | 16.30 | 3.38% | 3.56% | 6.76% | 618.77% | |
64 Neutral | HK$267.53B | 7.08 | 6.62% | 3.34% | -2.34% | 388.55% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
63 Neutral | HK$404.65B | 5.92 | 8.21% | 4.87% | 12.61% | 10.92% | |
62 Neutral | HK$15.00B | 7.38 | 4.00% | 6.45% | -28.06% | -23.13% | |
51 Neutral | HK$42.76B | -1.64 | -23.63% | 0.38% | -1.33% | -409.12% |
* Industrials Sector Average
HK:0656
Fosun International
5.21
-0.42
-7.38%
HK:0001
CK Hutchison Holdings
69.25
19.46
39.08%
HK:0267
CITIC
13.60
2.20
19.29%
HK:0053
Guoco Group
72.00
0.44
0.62%
HK:0363
Shanghai Industrial Holdings
13.90
0.53
3.96%
HK:0019
Swire Pacific
106.70
41.85
64.53%
Fosun International Corporate Events
Fosun Trims Indian Pharma Stake While Retaining Control
Sep 6, 2026
Fosun Pharma’s Singapore subsidiary has sold a 6.00% stake, or 9,897,000 shares, in its Indian target company via block trades and open market bids for about INR27.996 billion, equivalent to roughly USD0.294 billion. The sale, executed at an...
Fosun Restructures Capital Increase in Shangmeng Technology to Address Payment Licence Stability
Sep 1, 2026
Fosun International has revised its planned capital injection into Zhejiang Shangmeng Technology, shifting from a majority-control deal to a minority stake to address regulatory concerns around payment licence renewals. Instead of subscribing the ...
Fosun moves to spin off ClubMed Lifestyle in Hong Kong listing
Aug 28, 2026
Fosun International has applied to spin off its tourism subsidiary, ClubMed Lifestyle Group, for a separate listing on the Main Board of the Hong Kong Stock Exchange, with the bourse confirming that the proposed transaction may proceed. ClubMed Li...
Fosun Pharma Grants RSUs to 100 Employees Under 2025 Incentive Scheme
Aug 28, 2026
Fosun Pharma has approved a reserved grant of 1,695,400 H share restricted share units to 100 eligible employees under its 2025 H share RSU scheme, representing about 0.31% of its H shares in issue. The RSUs will vest in two equal tranches over 12...
Fosun International Grants 990,000 Share Options Under 2023 Incentive Scheme
Aug 28, 2026
Fosun International has granted 990,000 share options to four employees under its 2023 Option Scheme, with an exercise price of HK$5.41 per share, matching the stock’s closing price on the grant date and exceeding the five-day average. The o...
Fosun International Profit Jumps 160% on Core Business Strength
Aug 27, 2026
Fosun International reported broadly flat revenue of RMB86.96 billion for the first half of 2026, but delivered a sharp rebound in profitability as profit attributable to owners surged 160.3% year-on-year to RMB1.72 billion.Growth in the Health, I...
Fosun’s Yuyuan Sees Profit Surge Amid Revenue Decline in First Half 2026
Aug 20, 2026
Fosun International has highlighted interim results from key subsidiary Shanghai Yuyuan Tourist Mart (Group) Co., Ltd. for the six months to 30 June 2026, showing a mixed performance. Yuyuan’s operating revenue fell 10.96% year-on-year to RM...
Fosun International Sets August Board Meeting for Interim Results and Dividend Decision
Aug 12, 2026
Fosun International Limited has scheduled a board meeting for 27 August 2026 to approve the release of its interim results for the six months ended 30 June 2026. The meeting will also consider whether to declare an interim dividend, signaling pote...
Fosun International Signals Sharp Earnings Surge With Positive Profit Alert
Jul 29, 2026
Fosun International Limited, a Hong Kong-listed conglomerate, operates across multiple core industries and industrial businesses through its subsidiaries, seeking resilient sectors and steady improvements in operating quality. The group’s st...
Fosun International Reshapes Company Secretarial Team, Secures Listing Rules Waiver
Jun 30, 2026
Fosun International announced that company secretary and authorised representative Ms. Sze Mei Ming will resign with effect from 1 July 2026, with the board noting there is no disagreement and expressing appreciation for her contributions. The mov...
Fosun International Advances Spin-Off and Hong Kong Listing of Biopharma Unit Fosun Adgenvax
Jun 26, 2026
Fosun International and its pharmaceutical arm Fosun Pharma have obtained approval in principle from the Hong Kong Stock Exchange to proceed with the proposed spin-off and Main Board listing of biopharmaceutical subsidiary Fosun Adgenvax. Fosun Ad...
Fosun Alters Put Option Terms as Fosun Adgenvax Prepares Hong Kong Listing
Jun 15, 2026
Fosun International announced that its subsidiary Shanghai Fosun Pharmaceutical Industrial Development has signed supplemental agreements with shareholders of Fosun Adgenvax (Chengdu) Biopharmaceutical to terminate an existing put option, with an ...
Fosun International Updates Audit Committee Terms to Bolster Governance
Jun 12, 2026
Fosun International has updated the terms of reference for its Audit Committee, reflecting amendments approved by the board on several occasions since the committee’s adoption in 2007, most recently on 12 June 2026. The document outlines the...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.